Why Lipid Management Is a Specialty

Why is lipid management a specialty?

Lipid management has become a specialty because more than a dozen prescription options now exist, each with its own rules for dosing, side effects, labs, and coverage. Choosing, combining, and adjusting them to reach your target takes time and focus.

The goal of cholesterol treatment sounds simple: get LDL cholesterol (LDL-C) and ApoB low enough, and keep them there, so plaque stops building. Reaching it has gotten more detailed every year.

More options mean more people can reach their target. It also means more decisions: which medicine, which dose, which combination, what to do about side effects, what your genes say, and how to get it covered.

Primary care clinicians handle cholesterol well for many people, alongside blood pressure, diabetes, screenings, and everything else that comes up in a short visit. This guide explains why the harder cases take extra time, and what focused lipid care adds.

Much of the detail below comes from a two-part 2025 review of conventional and newer cholesterol treatments.

How many cholesterol medicines are there now?

As of October 2026, seven main prescription options lower LDL, alongside specialized drugs for rare conditions and triglycerides:

• Statins, the foundation. High-intensity doses (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) lower LDL by about 50% or more.
• Ezetimibe, a generic pill that blocks cholesterol absorption in the gut.
• Bempedoic acid (Nexletol), a pill that works in the liver's cholesterol pathway, with outcomes data in people who can't take statins.
• PCSK9 antibodies, Repatha and Praluent, self-injected every 2 to 4 weeks.
• Inclisiran (Leqvio), a shot given by a healthcare professional twice a year after two starting doses.
• Enlicitide (Lipfendra), the first PCSK9 inhibitor pill, approved in July 2026.
• Lerodalcibep (Lerochol), a once-monthly self-injection launched in the US in May 2026. The FDA approved an autoinjector pen on August 17, 2026, and its maker expects it in the US by January 2027.

Beyond those, specialized medicines treat rare inherited conditions, such as lomitapide and evinacumab for homozygous familial hypercholesterolemia, and others target triglycerides, such as icosapent ethyl and, for a rare disorder called familial chylomicronemia syndrome, olezarsen (Tryngolza, approved by the FDA in December 2024).

Each one has its own dosing, side effects, lab monitoring, and coverage rules. Our prescription cholesterol medications guide walks through them one by one.

How do you choose and combine cholesterol medicines?

The choice starts with how far you are from goal, what you've already tried, how you prefer to take medicine (pill, home shot, or clinic visit), and what your plan covers. Many people need more than one medicine to reach a demanding target.

A 20% gap might close with ezetimibe added to a statin. A 60% gap usually needs a PCSK9 option. Combinations matter too. For some people, a moderate statin dose plus ezetimibe is a good alternative to a high statin dose, and in studies the combination led to fewer people stopping treatment. Even the choice between the two most-used statins has tradeoffs, covered in rosuvastatin vs atorvastatin.

What LDL and ApoB targets apply to you?

Your target depends on your risk: under the 2026 ACC/AHA dyslipidemia guideline, LDL-C goals run from below 100 down to below 55 mg/dL, with matching ApoB goals of about 90, 70, and 55. The guideline brought back these specific goals, sorted by risk.

Working out which row you belong in takes your age, blood pressure, diabetes status, family history, Lp(a), and sometimes a coronary calcium score. The "normal range" on a lab report doesn't account for any of that.

What if statins cause side effects?

Often the answer is a structured rechallenge: a different statin, a lower dose, or a combination, before moving to non-statin options. Muscle symptoms are reported by roughly 10 to 25% of people taking statins, according to the 2025 review. In blinded trials, though, many of those symptoms also show up on placebo. So the question is often whether the statin, this statin, or this dose is the problem.

One structured approach is called SLAP: Switch to a different type of statin, Lower the dose, Alternate-day dosing with a long-acting statin, or Polypharmacy, meaning a lower statin dose paired with a non-statin medicine. Using approaches like this, the review notes, up to 70% of people previously labeled statin intolerant can resume therapy. People who truly can't now have several non-statin paths. Our statin intolerance program is built around this sequence.

Do statins interact with other medicines?

Some do, so the full medication list matters when picking one. Most statins are processed in the liver by enzymes that other medicines share. Simvastatin and lovastatin rely heavily on an enzyme called CYP3A4, and atorvastatin to a lesser extent, so some antibiotics, antifungals, heart rhythm drugs, and even large amounts of grapefruit juice can raise their levels. Rosuvastatin, pravastatin, and pitavastatin are much less affected by these enzymes, though they have transporter interactions of their own. Lomitapide also blocks CYP3A4, which limits how much of certain statins can be taken with it.

A clinician who sees everything you take can pick the statin that fits.

Why does high cholesterol run in some families?

Genes explain a lot of it, through familial hypercholesterolemia, Lp(a), or many small variants that add up. The main forms:

• Familial hypercholesterolemia (FH), a single-gene condition that raises LDL from birth. The CDC estimates it affects about 1 in 311 people. Finding it changes targets and urgency, and it means relatives should be tested too. See familial hypercholesterolemia.
• Lp(a), a particle set mostly by your genes. The 2026 guideline recommends measuring it at least once in adulthood. See what is Lp(a).
• Polygenic high cholesterol, where many small gene variants add up. This is common and explains why diet moves the number less for some people than they'd hope.

Can genes affect how you respond to a statin?

Yes. Variants in a few genes change how much statin reaches your blood and your risk of muscle symptoms.

The best-studied is SLCO1B1, which codes for a transporter that moves statins into the liver. A common variant (c.521T>C) reduces how well it works, which raises statin levels in the blood and the risk of muscle symptoms. Simvastatin is the most affected.

The 2022 CPIC guideline turns this into practical advice. For people with decreased or poor SLCO1B1 function, it recommends choosing a different statin over simvastatin (or keeping simvastatin under 20 mg a day if it's needed). It also gives dosing guidance for rosuvastatin based on a gene called ABCG2, and for fluvastatin based on CYP2C9.

Our statin pharmacogenomics guide covers what testing can and can't tell you. Preval Health offers optional longevity genetic testing at the first visit, covering cholesterol, statin-response, metabolic and other genes.

Why does insurance make you try other medicines first?

Most plans use step therapy, which means documented trials of cheaper medicines before they approve a newer one through prior authorization. Most plans require documented trials of a statin and often ezetimibe before covering a PCSK9 inhibitor or inclisiran, then ask for prior authorization with your diagnosis, recent labs, and the doses and dates of what you tried. A request missing one of those pieces often comes back denied, and the appeal adds weeks.

Manufacturer cash programs are another route. As of October 2026, Lerochol is $199 a month through its cash-pay program, Repatha is $239 a month through AmgenNow, and Merck set Lipfendra's list price at about $315 a month at its July 2026 approval (see our Lipfendra guide). Whether that beats your plan's copay depends on your plan. Our insurance and cash-pay pages explain both routes.

For Leqvio, the shot is given in person. Preval is working with infusion centers to offer Leqvio, so if it interests you, ask about availability in your area.

How often are labs rechecked on treatment?

US guidelines have recommended a repeat lipid panel about 4 to 12 weeks after a change, then periodically once you're stable. Starting a medicine is step one, and the next decision depends on that result: hold steady, raise the dose, add a second medicine, or switch. Several rounds of that loop are normal. Repeat labs also give insurers the follow-up results many plans ask for at renewal.

How does a lipid-only practice help?

It gives the details the time they need, from confirming a statin side effect to picking the right combination. Preval Health focuses only on prescription cholesterol care. Our treatment protocols are written by a board-certified preventive cardiologist, and licensed clinicians in our partner telehealth network evaluate you and prescribe. We're happy to work alongside your primary care clinician.

Because cholesterol is our only focus, there's time for the details: confirming whether a statin is really the cause of symptoms, picking a combination that fits, and checking labs every quarter.

Where to go next:

• Get a PCSK9 inhibitor prescription online
• Statin intolerance treatment
• Advanced lipid testing, including ApoB and Lp(a)
• How our cash practice works
• Rosuvastatin vs atorvastatin and statin pharmacogenomics